.treatment delays are also causing needless anxiety and distress to patients as well as putting lives at serious risk (file pic)
.previous efforts to treat babies with the same protein shortly after birth had failed, schneider said.
.
.
the provider paid out on 7,469 life and 1,769 critical illness claims in the year, with men accounting for 59 per cent of life claims and 47 per cent of critical illness claims.
.
erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
"this should not have happened and should never be allowed to happen again to another vulnerable person or their family.
.